Antiviral drug

Global Antiviral Therapeutics Markets & Technologies Report 2021: Approaches, Vaccines, Human Coronaviruses, Nanotechnology, Delivery, Competitive Landscape, 2020-2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 21, 2021
Infectious diseases, Biotechnology, Pharmaceutical, Health, Branches of biology, Biology, RNA, Life sciences, Gene expression, Antiviral drug, Biocides, RNA interference, Virus, Vaccine, Herpes simplex research, RNA silencing

Various antiviral approaches are described including pharmaceuticals and molecular biological therapies such as gene therapy and RNA interference (RNAi) as well as vaccines for virus infections.

Key Points: 
  • Various antiviral approaches are described including pharmaceuticals and molecular biological therapies such as gene therapy and RNA interference (RNAi) as well as vaccines for virus infections.
  • Various methods for local as well as systemic delivery of antiviral agents and vaccines are described.
  • These include major pharmaceutical companies (12), Biopharmaceutical companies with antiviral products (87), Antiviral drug companies (26) as well as viral vaccine companies (71).
  • The report is supplemented with 57 tables, 17 figures and 550 references from the literature.\n'

Global Dengue Vaccines Disease Market Analysis Report 2021-2022: Average Probability a Product Advances from Phase III is 68.5%

Retrieved on: 
Wednesday, April 21, 2021
Infectious diseases, Medical specialties, Clinical medicine, Vaccines, Dengue fever, Dengue vaccine, Antiviral drug

Given that most dengue-endemic regions consist of low-income countries, they are unlikely to implement the necessary serostatus screening programs that would allow identification of individuals eligible to receive Dengvaxia.

Key Points: 
  • Given that most dengue-endemic regions consist of low-income countries, they are unlikely to implement the necessary serostatus screening programs that would allow identification of individuals eligible to receive Dengvaxia.
  • TV003/TV005 remains behind TAK-003 in development, with a Phase III trial in Brazil assessing the vaccine\'s safety and efficacy expected to be completed in H2 2021.
  • Exportation to other dengue-endemic markets could also pose a serious strategic threat to Takeda\'s TAK-003.\nThe overall likelihood of approval of a Phase I antiviral asset is 12.9%, and the average probability a product advances from Phase III is 68.5%.
  • Antiviral products, on average, take 8.4 years from Phase I to approval, compared to 9.0 years in the overall infectious disease space.\n'

Appili Therapeutics to Present at the Bloom Burton & Co. Healthcare Investor Virtual Conference on Wednesday, April 21st, 2021

Retrieved on: 
Monday, April 19, 2021
Biotechnology, Pharmaceutical, Health, Chemistry, Physical sciences, Ebola, Chemical compounds, COVID-19, Favipiravir, Hydroxyarenes, Isomerism, Pyrazines, XC2, Antiviral drug, Infection

By systematically identifying urgent infections with unmet needs, Appili\xe2\x80\x99s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives.

Key Points: 
  • By systematically identifying urgent infections with unmet needs, Appili\xe2\x80\x99s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives.
  • As part of a global consortium, Appili is sponsoring late-stage clinical trials evaluating the antiviral Avigan\xc2\xae / REEQONUSTM (favipiravir) for the worldwide treatment and prevention of COVID-19.
  • Led by a proven management team, Appili is at the epicenter of the global fight against infection.
  • For more information, visit www.AppiliTherapeutics.com .\nBloom Burton & Co. (Bloom Burton Securities Inc.) is a firm dedicated to accelerating returns in the healthcare sector for both investors and companies.

Global Dengue Vaccines Disease Analysis Report 2021-2022: Approvals of TV003/TV005 and Domestic Vaccines will Lead to Considerable Competition - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 15, 2021
Infectious diseases, Pharmaceutical, Health, Medical specialties, Clinical medicine, Medicine, Vaccination, Virology, Vaccines, Dengue fever, Dengue vaccine, Vaccine, Attenuated vaccine, Antiviral drug, Merck & Co.

b'The "Disease Analysis: Dengue Vaccines" report has been added to ResearchAndMarkets.com\'s offering.\nThe dengue vaccines market is expected to expand rapidly following the anticipated launch of TAK-003 in 2021/22.\nThe pipeline remains active with two late-phase live-attenuated vaccines (LAVs), Takeda\'s TAK-003 and Merck & Co\'s TV003/TV005, in development in dengue-endemic regions.

Key Points: 
  • b'The "Disease Analysis: Dengue Vaccines" report has been added to ResearchAndMarkets.com\'s offering.\nThe dengue vaccines market is expected to expand rapidly following the anticipated launch of TAK-003 in 2021/22.\nThe pipeline remains active with two late-phase live-attenuated vaccines (LAVs), Takeda\'s TAK-003 and Merck & Co\'s TV003/TV005, in development in dengue-endemic regions.
  • Given that most dengue-endemic regions consist of low-income countries, they are unlikely to implement the necessary serostatus screening programs that would allow identification of individuals eligible to receive Dengvaxia.
  • TV003/TV005 remains behind TAK-003 in development, with a Phase III trial in Brazil assessing the vaccine\'s safety and efficacy expected to be completed in H2 2021.
  • Antiviral products, on average, take 8.4 years from Phase I to approval, compared to 9.0 years in the overall infectious disease space.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210415005792/en/\n'

Bold Therapeutics' BOLD-100 Effective In Vitro Against COVID-19 Variants

Retrieved on: 
Friday, April 16, 2021
Drug discovery, Pharmaceutical industry, COVID-19 pandemic in the United Kingdom, Lineage B.1.1.7, Preclinical development, In vitro, In vivo, Antiviral drug, Health sciences, Life sciences, Biology

New in vitro research completed by Bold Therapeutics\' collaborators at the University of British Columbia and Western University showed that BOLD-100 consistently reduced viral concentrations in multiple COVID-19 variants, including the highly prevalent B.1.1.7 variant originally identified in the UK (see Figure 1).

Key Points: 
  • New in vitro research completed by Bold Therapeutics\' collaborators at the University of British Columbia and Western University showed that BOLD-100 consistently reduced viral concentrations in multiple COVID-19 variants, including the highly prevalent B.1.1.7 variant originally identified in the UK (see Figure 1).
  • This work confirms and expands upon prior research demonstrating that BOLD-100 has strong antiviral activity against COVID-19 in a range of preclinical in vitro models.
  • Since that time, Bold Therapeutics has generated additional efficacy and safety data, including the aforementioned variant studies, and is currently completing in vivo studies of BOLD-100.
  • In parallel, Bold Therapeutics continues to enroll patients in its Phase 1b study of BOLD-100 in the treatment of advanced gastrointestinal cancers.

Cidara Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference

Retrieved on: 
Wednesday, April 7, 2021
Biocides, Epidemiology, Antiviral drug, Medical specialties, Infection, Influenza, Health sciences, Health

Cidara is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections.

Key Points: 
  • Cidara is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections.
  • The Companys portfolio is comprised of its lead antifungal candidate, rezafungin, in addition to antiviral conjugates (AVCs) for the prevention and treatment of influenza and other viral diseases from Cidaras proprietary Cloudbreak antiviral platform.
  • Cidara is headquartered in San Diego, California.
  • For more information, please visit www.cidara.com .

Cidara Therapeutics Announces Agreement with Janssen to Develop and Commercialize AVCs for the Prevention and Treatment of Influenza

Retrieved on: 
Monday, April 5, 2021
Articles, Health, Medical specialties, Flu season, Influenza, Seasonality, Severe acute respiratory syndrome, Antiviral drug, Pandemic, Influenza A virus subtype H1N1

Cidara will receive an upfront payment of $27 million and Janssen will fund all future research, development, manufacturing and commercialization for CD388.

Key Points: 
  • Cidara will receive an upfront payment of $27 million and Janssen will fund all future research, development, manufacturing and commercialization for CD388.
  • Importantly, this agreement validates our Cloudbreak antiviral platform as we continue to advance our AVC programs in RSV, HIV and SARS-CoV-2.
  • AVCs being studied for the prevention and treatment of seasonal and pandemic influenza have the potential to deliver universal protection for an entire flu season.
  • Cidara is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections.

LightAir IonFlow air purifier effectively reduces the infectivity of viruses that mimic coronaviruses

Retrieved on: 
Wednesday, March 31, 2021
Medical specialties, Medicine, Health sciences, Animal virology, Virology, Epidemiology, Pandemics, Virus, Zoonoses, Coronavirus, Antiviral drug

This evidence can now be added to a seven-year scientific study from Karolinska Institute that previously showed the technology's effectiveness against airborne viruses and how it greatly reduces the spread of infection.

Key Points: 
  • This evidence can now be added to a seven-year scientific study from Karolinska Institute that previously showed the technology's effectiveness against airborne viruses and how it greatly reduces the spread of infection.
  • "We measured out various versions of pseudoviruses* that mimic the entry of different coronaviruses into cells.
  • "Personally, I find this extremely interesting, and the potential of this technology to combat virus spreading should be further investigated.
  • Not least in these times, and especially given that this technology attacks the viral entry process so viruses can no longer infect human cells."

LightAir IonFlow air purifier effectively reduces the infectivity of viruses that mimic coronaviruses

Retrieved on: 
Wednesday, March 31, 2021
Medical specialties, Medicine, Health sciences, Animal virology, Virology, Epidemiology, Pandemics, Virus, Zoonoses, Coronavirus, Antiviral drug

This evidence can now be added to a seven-year scientific study from Karolinska Institute that previously showed the technology's effectiveness against airborne viruses and how it greatly reduces the spread of infection.

Key Points: 
  • This evidence can now be added to a seven-year scientific study from Karolinska Institute that previously showed the technology's effectiveness against airborne viruses and how it greatly reduces the spread of infection.
  • "We measured out various versions of pseudoviruses* that mimic the entry of different coronaviruses into cells.
  • "Personally, I find this extremely interesting, and the potential of this technology to combat virus spreading should be further investigated.
  • Not least in these times, and especially given that this technology attacks the viral entry process so viruses can no longer infect human cells."

Model Medicines announces AI-driven drug discovery partnership with Sanford Burnham Prebys

Retrieved on: 
Tuesday, March 23, 2021
Pharmaceutical industry, Life sciences, La Jolla, San Diego, Stem cell research, Health sciences, Sanford Burnham Prebys Medical Discovery Institute, Drug discovery, Health care, Antiviral drug, Drug development, Medication

LA JOLLA, Calif., March 23, 2021 /PRNewswire/ --Model Medicines, an AI drug discovery software company, today announced they have entered into a multi-target collaboration agreement with Sanford Burnham Prebys Medical Discovery Institute to identify and develop drugs for novel antiviral targets.

Key Points: 
  • LA JOLLA, Calif., March 23, 2021 /PRNewswire/ --Model Medicines, an AI drug discovery software company, today announced they have entered into a multi-target collaboration agreement with Sanford Burnham Prebys Medical Discovery Institute to identify and develop drugs for novel antiviral targets.
  • The collaboration leverages Model Medicines' ActivPred AI Drug Discovery Platform, an unbiased drug, target, and disease agnostic digital chemistry engine, in conjunction with Sanford Burnham Prebys' identification of novel antiviral targets and deep scientific expertise, to discover and develop new treatments for SARS-CoV-2 and other infectious diseases.
  • Model Medicines has created an infectious disease specific version of their ActivPred AI Drug Discovery Platform that focuses exclusively on identifying safe and effective, non-obvious therapeutics with activity against the novel biological targets identified by Sanford Burnham Prebys.
  • Model Medicines is transforming drug discovery by leveraging the historical compendium of drug development data, a drug and disease agnostic discovery platform, and unbiased AI to create Phase II/III ready drug candidates in months rather than years.